Segment, Geographical and Other Revenue Information (Tables)

3 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Schedule of segment reporting

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):

	Three months ended March 31, 2019								Three months ended March 31, 2018
	Performance Enzymes			Novel Biotherapeutics		Total			Performance Enzymes			Novel Biotherapeutics		Total
Revenues:
Product revenue	$	7,988		$	—	$	7,988		$	6,163		$	—	$	6,163
Research and development revenue	2,099			5,496		7,595			4,566			3,313		7,879
Total revenues	10,087			5,496		15,583			10,729			3,313		14,042
Costs and operating expenses:
Cost of product revenue	4,391			—		4,391			3,825			—		3,825
Research and development(1)	4,442			3,317		7,759			5,066			1,932		6,998
Selling, general and administrative	2,101			517		2,618			2,096			146		2,242
Total segment costs and operating expenses	10,934			3,834		14,768			10,987			2,078		13,065
Income (loss) from operations	$	(847	)	$	1,662	$	815		$	(258	)	$	1,235	$	977
Corporate costs (2)						(5,575		)						(5,435		)
Depreciation and amortization						(373		)						(238		)
Loss before income taxes						$	(5,133	)						$	(4,696	)

⁽¹⁾ Research and development expenses exclude depreciation.

⁽²⁾ Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):

	Three months ended March 31, 2019						Three months ended March 31, 2018
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Stock-based compensation	$	636	$	141	$	777	$	333	$	63	$	396

Schedule of customers that contributed 10% or more of total accounts receivable

Customers that each contributed 10% or more of our total revenues were as follows:

	Percentage of Total Revenues
	For the three months ended March 31,
	2019	2018
Customer A	41%	48%
Customer B	35%	24%
Customer C	*	10%

Customers that each contributed 10% or more of our total accounts receivable had the following balances as of the periods presented:

	Percentage of Accounts Receivables as of
	March 31, 2019	December 31, 2018
Customer A	33%	37%
Customer B	30%	17%
Customer D	17%	*
Customer E	*	11%
Customer F	*	16%

* Less than 10% of the period presented

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):

	Three Months Ended March 31,
	2019		2018
Revenues
Americas	$	2,838	$	3,597
EMEA	7,726		4,992
APAC	5,019		5,453
Total revenues	$	15,583	$	14,042

Schedule of long-lived assets by geographical area

Identifiable long-lived assets by location and goodwill by reporting unit were as follows:

Long-lived assets:	March 31, 2019		December 31, 2018
United States	$	30,886	$	4,759

Schedule of intangible assets and goodwill

	As of March 31, 2019 and December 31, 2018
	Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241